

## Erratum

---

# Erratum to: Inflammatory breast cancer with excellent response to pembrolizumab-chemotherapy combination: A case report

Zeni Kharel<sup>a,\*</sup>, Omar P. Nemer<sup>b</sup>, Wang Xi<sup>c</sup>, Bimala Upadhayaya<sup>d</sup>, Carla I. Falkson<sup>d</sup>, Ruth M. O'Regan<sup>d</sup> and Ajay Dhakal<sup>d</sup>

<sup>a</sup>*Department of Internal Medicine, Rochester General Hospital, Rochester, NY, USA*

<sup>b</sup>*Department of Radiology, University of Rochester Medical Center, Rochester, NY, USA*

<sup>c</sup>*Department of Pathology, University of Rochester Medical Center, Rochester, NY, USA*

<sup>d</sup>*Department of Medicine, University of Rochester Medical Center, Rochester, NY, USA*

[Breast Disease, **41**(1) 2022, 255–260, 10.3233/BD-210041] <https://content.iospress.com/articles/breast-disease/bd210041>

On p. 258, the sentence “Pembrolizumab is a PD-L1 monoclonal antibody.” should read “Pembrolizumab is an anti-PD-1 monoclonal antibody.”

---

\*Corresponding author: Zeni Kharel, E-mail: zenikharel11@gmail.com.